Explaining the Importance of Molecular Testing to Patients With NSCLC

Presented by

Sponsored by

The Academy of Oncology Nurse & Patient Navigators (AONN+) is pleased to introduce an educational video in which expert nurse navigators and nurse practitioners discuss how to explain the importance of molecular testing to patients with resectable or metastatic non-small cell lung cancer in a way that patients and caregivers can understand.

This video is part 3 of a 5-part educational video series we’ve produced in partnership with AstraZeneca. Topics of discussion in this video include:

• How do you explain the importance of molecular testing to patients?
• What are some of the challenges you see with molecular testing and how are you overcoming them?
• How does your institution handle molecular testing in resectable non-small cell lung cancer?
• How do you handle molecular testing in metastatic non-small cell lung cancer?
• What do you most want community nurse navigators and nurse practitioners to know about molecular testing for patients with resectable and metastatic non-small cell lung cancer?

Explaining the Importance of Molecular Testing to Patients With NSCLC

Lung Cancer Education Resources

Benjamin Levy, MD

Kim Rohan, ANP-BC, AOCN

Claudia T. Miller, BSN, RN, OCN, ONN-CG

Lauren Welch, MSN, NP-C, AOCNP

Holly Chitwood

Rasheda Persinger, MSN, NP-C

Panelists include:

Benjamin Levy, MD
Associate Professor
Johns Hopkins School of Medicine
Clinical Director of Medical Oncology
Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital

Holly Chitwood, DNP, APRN, FNP-C, AGACNP-BC
University of Kentucky Markey Cancer Center

Kim Rohan, ANP-BC, AOCN
Edward Hospital & Health Services

Lauren Welch, MSN, NP-C, AOCNP
Tennessee Oncology/Sarah Cannon Research Institute

Claudia Miller, BSN, RN, OCN, ONN-CG
Medical University of South Carolina

Rasheda Persinger, MSN, NP-C
Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital

DISCLAIMER

The views and opinions expressed in this video are those of the individual oncology specialists and do not represent the views or opinions of AstraZeneca. This video contains anecdotal information gathered from a discussion with oncology specialists based on their opinions/experiences. Recommendations are general and may vary with patients. At the time of the filming, the healthcare professionals featured were in the roles and at the institutions indicated.

Related Articles

Keeping Patients on Track Throughout the Unresectable Stage III Treatment Journey

Benjamin Levy, MD, Kim Rohan, ANP-BC, AOCN, Lauren Welch, MSN, NP-C, AOCNP, Claudia T. Miller, BSN, RN, OCN, ONN-CG, Rasheda Persinger, MSN, NP-C

|

Lung Cancer Education Resources

Helping to Support Optimal Care in Small Cell Lung Cancer

Benjamin Levy, MD, Holly Chitwood, Kim Rohan, ANP-BC, AOCN, Lauren Welch, MSN, NP-C, AOCNP, Claudia T. Miller, BSN, RN, OCN, ONN-CG

|

Lung Cancer Education Resources

Availability and Accessibility of Cancer Care Delivery Approaches to Reduce Financial Toxicity of Rural and Urban Cancer Patients in Kentucky

Jean Edward, PhD, RN, CHPE, William Bowling, BA, Holly Chitwood, Robin Vanderpool, DrPH

|

May 2022 Vol 13, No 5

A study of healthcare staff perspectives of financial toxicity experienced by cancer patients and staff- and systems-level cancer care delivery approaches for addressing financial toxicity.

Last modified: August 10, 2023